Stopping Mood-Stabilizer Maintenance After Years of Stability
A single patient, six years stable on lithium, asking to stop before recording her first album. Her complaint about blunted creativity is real and documented, not denial — and it sits against relapse data that is just as real.
E.C. is a 33-year-old singer-songwriter who has been stable on lithium for six years since her last manic episode in her mid-twenties, when a booking agent found her three days into a stretch without sleep, convinced she had written an album's worth of material good enough to skip her usual label entirely. She has had no further episodes since starting lithium and has built a modest but real touring career in the years since. She comes to this appointment asking to stop the medication entirely, timed around starting to record her first full-length album next month. Her reason isn't forgetfulness or denial about her diagnosis — she describes, specifically and consistently across the last several visits, a flattening of emotional range and a creative output she experiences as thinner than it was before lithium, and she is worried about walking into a recording studio without access to the intensity she used to write from.
This is not a complaint to wave away as a known side-effect she should simply tolerate. Reports of blunted affect and reduced creative output on lithium are real and documented, not universal but not rare either, and they matter differently to a working musician than they would to most patients. Set against that is relapse data that is equally real: patients with bipolar I stopping lithium after years of stability still relapse at substantial rates within one to two years, with the risk meaningfully higher when the drug is stopped abruptly rather than tapered gradually. She is not asking whether stopping carries risk — she has read enough to know it does — she is asking whether that risk is one she gets to decide is worth taking for a part of her identity that matters this much to her.
Weighing a patient-reported cost against relapse risk
I want to be direct about the relapse numbers before anything else gets decided: this is not a small risk she is weighing, and an abrupt stop specifically carries a higher rebound-risk than a gradual taper does. If she stops, the way she stops matters as much as the decision itself.
I am not dismissing her creativity concern as invalid — I am saying the discontinuation-method question and the stay-on-a-mood-stabilizer-or-not question are separate decisions, and the field has real data on the first one that should shape whatever she chooses on the second.
I've heard this complaint from her consistently, across several visits, in specific and concrete terms about her writing process — that is a real clinical finding, not something to manage by reassurance. But stopping mood-stabilizer coverage entirely, right before the most demanding professional and personal stretch of her year, is a specific kind of bad timing even if her underlying concern is legitimate.
A switch to a mood stabilizer with less reputation for cognitive and affective blunting, rather than no mood stabilizer at all, addresses the actual complaint — but I want to be honest about what it doesn't fix. Lamotrigine's own maintenance-trial evidence is asymmetric: it reliably delays a depressive relapse and has shown no significant benefit over placebo for delaying a manic one. Her single episode was manic, not depressive, so this switch is not a like-for-like substitute for what lithium was actually protecting her against.
If a switch is the direction, it has to be a real cross-taper, not lithium stopped while lamotrigine is started at a subtherapeutic dose — lamotrigine's own titration schedule is slow by design to limit rash risk, so there is a real window where neither drug is providing full coverage unless the taper is planned around that gap explicitly.
A gradual cross-taper agreed upon: lamotrigine started now at a slow, standard titration, with lithium held at its current dose until lamotrigine reaches an adequate level, and only then tapered down gradually rather than stopped. The plan is timed to have lamotrigine established before her album recording begins, not to have her unprotected during it. Because lamotrigine does not carry lithium's antimanic protection, follow-up after the taper completes was set to screen explicitly for early manic symptoms — decreased need for sleep, racing thoughts, grandiosity — not just for the depressive or affective-blunting concerns that prompted the switch.
Whether she eventually wants to come off mood-stabilizer coverage entirely was left open rather than decided today — she was clear that lamotrigine is a compromise she is willing to try, not a final answer to the creativity concern she raised, and the team agreed to revisit that specific question again once she has had real time to assess how lamotrigine feels compared to lithium.